Loading
The report that tells a patient their tumour's mutations should also tell them which trials are recruiting for those mutations within reach, with the status checked that week rather than copied from a stale list.
Genomic testing laboratories would embed a matching step at report generation: variants are mapped to trial arms (OncoKB and CIViC annotations, ClinicalTrials.gov structured eligibility), filtered by geography and current recruiting status confirmed by direct query, and listed with a contact. Some commercial reports do this partly; the idea makes live status confirmation and geography the standard, with the same section in public-lab reports.
Shares Caris Life Sciences, OncoKB, Foundation Medicine (Roche), Tempus AI.
Shares Foundation Medicine (Roche), Tempus AI, Guardant Health, Next-generation sequencing (NGS).
Shares Foundation Medicine (Roche), Guardant Health, Trials enrol too few, too slowly, Comprehensive genomic profiling.
Shares Tempus AI, ClinicalTrials.gov, AI trial matching & clinical decision support, Trials enrol too few, too slowly.
Shares Foundation Medicine (Roche), Guardant Health, Knowledge reaches practice too slowly.
Shares OncoKB, ClinicalTrials.gov, Knowledge reaches practice too slowly, CIViC.
Shares ClinicalTrials.gov, AI trial matching & clinical decision support, Trials enrol too few, too slowly.
Shares Caris Life Sciences, Companion diagnostics, Next-generation sequencing (NGS), Comprehensive genomic profiling.